Lead with your gut.

Stellate Therapeutics develops small molecules produced by human gut bacteria into first-in-class personalized therapies for neurological diseases.

Use the gut-brain connection to change the trajectory of disease.

Due to millions of years of coevolution, humans count on our gut bacteria to maintain our health.

Stellate Therapeutics uses the human microbiome as a source of small molecule therapies for devastating diseases, starting with neurological disorders.

Pipeline

Microbiome medicines to modify disease.

Our lead candidate, STL-101 is a potential first-in-class, disease-modifying therapy for Parkinson’s and Alzheimer’s disease.

Management & Strategic Advisory Board

Nicole McKnight PhD

CEO

David Immke PhD

CSO

Patrice Garnier PhD

President

Antoine Danchin PhD

Scientific Founder

Bernard Munos MBA, MS

Robert Schneider PhD

Alexandre Mouradian

Eric Fourmentin

Team

Nicole McKnight PhD

CEO

David Immke PhD

CSO

Jonathan Weiss PhD, MBA

Director, Business Development

Patricia Richard PhD

Director, Neuroscience

Xavier Manière PharmD, PhD

Director, Discovery Biology

Sabriya Stukes PhD

Operations Director

Scientific Advisory Board

Géraldine Androdias MD

Sahar El Aidy PhD

Michael Spedding PhD